Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
Completed
Bristol-Myers Squibb
Phase 1
2014-11-01
Apixaban is an anticoagulant (also known as blood thinner) approved by the Food and Drug
Administration (FDA) for reducing the risk of stroke and systemic embolism in patients with
non-valvular atrial fibrillation. It has no reliable method of reversal. Kcentra is an FDA
approved drug derived from blood that is used as an antidote to treat people with bleeding
associated with taking the well-known anticoagulant warfarin. This is a Phase I,
placebo-controlled, single site, open-label, crossover trial to evaluate the reversibility
apixaban anticoagulation with Kcentra.
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
Completed
CSL Behring
Phase 1
2014-11-01
Apixaban is an anticoagulant (also known as blood thinner) approved by the Food and Drug
Administration (FDA) for reducing the risk of stroke and systemic embolism in patients with
non-valvular atrial fibrillation. It has no reliable method of reversal. Kcentra is an FDA
approved drug derived from blood that is used as an antidote to treat people with bleeding
associated with taking the well-known anticoagulant warfarin. This is a Phase I,
placebo-controlled, single site, open-label, crossover trial to evaluate the reversibility
apixaban anticoagulation with Kcentra.
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
Completed
Thomas Jefferson University
Phase 1
2014-11-01
Apixaban is an anticoagulant (also known as blood thinner) approved by the Food and Drug
Administration (FDA) for reducing the risk of stroke and systemic embolism in patients with
non-valvular atrial fibrillation. It has no reliable method of reversal. Kcentra is an FDA
approved drug derived from blood that is used as an antidote to treat people with bleeding
associated with taking the well-known anticoagulant warfarin. This is a Phase I,
placebo-controlled, single site, open-label, crossover trial to evaluate the reversibility
apixaban anticoagulation with Kcentra.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
